McNaughton Wealth Management LLC Has $485,000 Position in Johnson & Johnson (NYSE:JNJ)

McNaughton Wealth Management LLC grew its holdings in shares of Johnson & Johnson (NYSE:JNJGet Rating) by 9.9% in the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,735 shares of the company’s stock after acquiring an additional 247 shares during the period. McNaughton Wealth Management LLC’s holdings in Johnson & Johnson were worth $485,000 as of its most recent SEC filing.

A number of other institutional investors have also modified their holdings of the business. Ulland Investment Advisors LLC acquired a new stake in shares of Johnson & Johnson in the 4th quarter valued at about $296,000. Castle Rock Wealth Management LLC grew its stake in shares of Johnson & Johnson by 3.9% in the 4th quarter. Castle Rock Wealth Management LLC now owns 12,855 shares of the company’s stock valued at $2,119,000 after buying an additional 479 shares during the period. Rehmann Capital Advisory Group lifted its position in Johnson & Johnson by 3.2% in the 4th quarter. Rehmann Capital Advisory Group now owns 43,045 shares of the company’s stock valued at $7,364,000 after acquiring an additional 1,348 shares in the last quarter. Lynch Asset Management Inc. bought a new position in Johnson & Johnson in the 4th quarter valued at about $1,625,000. Finally, Richwood Investment Advisors LLC bought a new position in Johnson & Johnson in the 4th quarter valued at about $664,000. Hedge funds and other institutional investors own 68.78% of the company’s stock.

Several equities analysts recently weighed in on JNJ shares. StockNews.com raised shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, May 17th. Sanford C. Bernstein cut shares of Johnson & Johnson from an “outperform” rating to a “market perform” rating and raised their price target for the company from $180.00 to $183.00 in a research report on Wednesday, March 16th. Raymond James raised their price target on shares of Johnson & Johnson from $195.00 to $196.00 and gave the company an “outperform” rating in a research report on Wednesday, April 20th. Bank of America started coverage on shares of Johnson & Johnson in a research report on Wednesday, March 2nd. They set a “neutral” rating on the stock. Finally, The Goldman Sachs Group lifted their target price on shares of Johnson & Johnson from $163.00 to $181.00 and gave the stock a “neutral” rating in a research report on Tuesday, April 12th. Four research analysts have rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $190.50.

NYSE:JNJ opened at $175.74 on Thursday. The company has a current ratio of 1.39, a quick ratio of 1.14 and a debt-to-equity ratio of 0.39. The stock has a market capitalization of $462.44 billion, a PE ratio of 23.68, a price-to-earnings-growth ratio of 3.35 and a beta of 0.66. The firm’s 50 day moving average is $177.66 and its 200 day moving average is $173.09. Johnson & Johnson has a 12 month low of $155.72 and a 12 month high of $186.69.

Johnson & Johnson (NYSE:JNJGet Rating) last posted its quarterly earnings results on Tuesday, April 19th. The company reported $2.67 EPS for the quarter, topping analysts’ consensus estimates of $2.60 by $0.07. The company had revenue of $23.43 billion for the quarter, compared to analysts’ expectations of $23.62 billion. Johnson & Johnson had a net margin of 20.90% and a return on equity of 36.59%. Johnson & Johnson’s revenue was up 5.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.59 EPS. Research analysts predict that Johnson & Johnson will post 10.23 earnings per share for the current year.

The business also recently declared a quarterly dividend, which was paid on Tuesday, June 7th. Investors of record on Tuesday, May 24th were issued a $1.13 dividend. This represents a $4.52 dividend on an annualized basis and a dividend yield of 2.57%. The ex-dividend date was Monday, May 23rd. This is a boost from Johnson & Johnson’s previous quarterly dividend of $1.06. Johnson & Johnson’s payout ratio is 60.92%.

In related news, EVP Kathryn E. Wengel sold 40,000 shares of Johnson & Johnson stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $173.00, for a total value of $6,920,000.00. Following the completion of the transaction, the executive vice president now directly owns 71,311 shares in the company, valued at approximately $12,336,803. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider William Hait sold 29,699 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, April 21st. The shares were sold at an average price of $183.58, for a total transaction of $5,452,142.42. Following the completion of the transaction, the insider now owns 80,236 shares of the company’s stock, valued at $14,729,724.88. The disclosure for this sale can be found here. Insiders sold a total of 78,161 shares of company stock worth $13,895,302 in the last ninety days. 0.35% of the stock is currently owned by insiders.

Johnson & Johnson Profile (Get Rating)

Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide. The company's Consumer Health segment offers baby care products under the JOHNSON'S and AVEENO Baby brands; oral care products under the LISTERINE brand; skin health/beauty products under the AVEENO, CLEAN & CLEAR, DR.

See Also

Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJGet Rating).

Institutional Ownership by Quarter for Johnson & Johnson (NYSE:JNJ)

Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.